B. Riley Wealth Advisors Inc. Has $760,000 Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

B. Riley Wealth Advisors Inc. grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 97.0% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 1,838 shares of the company's stock after buying an additional 905 shares during the period. B. Riley Wealth Advisors Inc.'s holdings in IDEXX Laboratories were worth $760,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Hurley Capital LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at $29,000. Rialto Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at $30,000. Colonial Trust Co SC increased its stake in shares of IDEXX Laboratories by 84.8% in the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock valued at $35,000 after buying an additional 39 shares during the period. Kestra Investment Management LLC acquired a new stake in shares of IDEXX Laboratories in the 4th quarter valued at $38,000. Finally, Itau Unibanco Holding S.A. increased its stake in shares of IDEXX Laboratories by 540.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after buying an additional 81 shares during the period. 87.84% of the stock is owned by institutional investors and hedge funds.

IDEXX Laboratories Trading Down 0.6%

NASDAQ:IDXX traded down $3.03 on Friday, reaching $512.52. The company's stock had a trading volume of 1,221,827 shares, compared to its average volume of 652,599. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $530.60. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31. The firm has a market cap of $41.22 billion, a PE ratio of 48.03, a PEG ratio of 3.41 and a beta of 1.52. The business's 50-day moving average price is $449.80 and its two-hundred day moving average price is $437.32.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The firm had revenue of $998.43 million during the quarter, compared to analysts' expectations of $998.25 million. During the same period in the previous year, the firm earned $2.71 earnings per share. The company's revenue was up 3.6% on a year-over-year basis. Equities research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

IDXX has been the subject of a number of analyst reports. Bank of America lifted their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 4th. Morgan Stanley lifted their price objective on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research note on Monday, May 5th. Piper Sandler lifted their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research note on Monday, February 10th. Stifel Nicolaus lifted their price objective on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research note on Monday, May 19th. Finally, Barclays lifted their price objective on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 4th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $536.00.

Insider Buying and Selling at IDEXX Laboratories

In other news, Director M Anne Szostak sold 1,046 shares of the company's stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $513.74, for a total transaction of $537,372.04. Following the completion of the transaction, the director now directly owns 262 shares of the company's stock, valued at $134,599.88. This represents a 79.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 0.98% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.